PIK3CA and neoplasm: Indeed, it has been reported that non-continuous dosing on every 3rd or 4th day with high doses of the PI3K inhibitor GDC-0941, in combination with the MEK inhibitors PD 0325901 or GDC-0973, resulted in marked tumour growth inhibition, and potentially reduced toxicity [6], [19].